Hepatitis B vaccines are mainly divided into five types: blood-borne hepatitis B vaccine, genetically engineered (recombinant) hepatitis B vaccine, synthetic hepatitis B peptide vaccine, conjugate vaccine and DNA vaccine. Engerix-B, abbreviated as Hep-B (ENG), is a non-infectious conjugate DNA vaccine containing HBSAG, which is a product of genetically engineered brewer’s yeast and has been in use since the mid-1980s with at least ten years of immune protection. The seroprotection rate of Hep-B(ENG) in healthy newborns and young children was high using the 3-dose 0,1,6 regimen, and the seroprotection rate was 92.6%-100% one month after the last dose of 10ug of Hep-B(ENG) inoculation from newborns to 10-month-old infants. In 1996, CHO recombinant hepatitis B vaccine and yeast recombinant hepatitis B vaccine were put on the market in China, and the effect of this vaccine in blocking perinatal transmission was better than that of blood-derived hepatitis B vaccine at the same dose or even at a low dose, with a blocking rate of 80%-90%, and the surface antibody induced by 5ug of vaccine was similar to that of 10ug of blood-derived vaccine. Most scholars believe that although surface antibodies may turn negative after hepatitis B vaccination, the body recognizes the rapid production of surface antibodies when exposed to HBV due to the existence of immune memory, which is a strong immune barrier to reinfection, so all newborns should be immunized with hepatitis B vaccine in a timely manner and without the need for booster immunization. Adults should be vaccinated with high doses of hepatitis B vaccine, with 20ug of recombinant (CHO cell) hepatitis B vaccine recommended, and 0, 1, and 6 regimens preferred, and Hep-B (ENG) in healthy individuals produces high seroprotection rates. In some cases where rapid vaccination is needed, such as for travelers in areas with a high prevalence of hepatitis B and those exposed accidentally to hepatitis B, the regimen is: Hep-B(ENG) 20ug, 0, 1, 2, 12 months for adults, with a seroprotection rate of 84%-100% 3 months after the first dose of this regimen, Hep-B(ENG) 20ug or PDV-hep 20ug, at 0, 1, 2 months. The seroprotection rate was 100% at month 13 for both regimens, with a booster dose of Hep-B(ENG) given at months 0, 1, and 2. Hepatitis B vaccination in special populations There was no significant difference between genetic hepatitis B vaccine alone and combined hepatitis B immunoglobulin (HBIG) in terms of whether the mother was double-positive or single-positive and the rate of positive surface antibody conversion, but there was a significant difference in the rate of surface antibody-like conversion 3 months after immunization, with the combined application being significantly better than hepatitis B vaccine alone. The combined application of HBIG did not increase the long-term immunization effect of hepatitis B vaccine. Hep-B (ENG) should be administered immediately at birth to newborns whose mothers are HBV carriers to prevent vertical transmission from mother to child. Newborns whose mothers are HBeAg and HBsAg positive should be actively and passively immunized (HBIG+Hep-B(ENG)) or actively [with Hep-B(ENG) only] immunized by 10ug of Hep-B(ENG) or PDV-Vax at 0, 1, and 6 months of age had antibody production in 93.6% and 94.3%, respectively. The complete Hep-B(ENG) vaccination regimen seroprotects for up to 10 years.